Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

10.2K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Proteomic Analysis of Cerebrospinal Fluid From Neurological Patients With and Without Amyotrophic Lateral Sclerosis.

Journal of neurochemistry·2026
Same author

Myosin Post-Translational Modifications Associated With Critical Illness Myopathy.

Acta physiologica (Oxford, England)·2026
Same author

Systems neuroendocrinology in ME/CFS and long COVID: a chronobiological framework for hormone-based research.

Frontiers in neuroendocrinology·2026
Same author

Combatting ventilator induced diaphragm dysfunction with human bone marrow mesenchymal stromal cell-derived extracellular vesicles.

Skeletal muscle·2026
Same author

Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.

Brain : a journal of neurology·2026
Same author

Proteomic signatures in cerebrospinal fluid and their clinical associations in patients with ME/CFS.

Scientific reports·2026
Same journal

Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Molecular Basis of Disease Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

General Subjects Cumulative Contents.

Biochimica et biophysica acta·2020
Same journal

Erratum to 'on the role of exchangeable hydrogen bonds for the kinetics of P680<sup>+·</sup> Q<sub>A</sub> <sup>-·</sup> formation and P680<sup>+·</sup> Pheo<sup>-·</sup> recombination in photosystem II' [Biochim. Biophys. Acta 1276 (1996) 35-44].

Biochimica et biophysica acta·2019
Same journal

Oligomeric state of the light-harvesting complexes B800-850 and B875 from purple bacterium Rubrivivax gelatinosus in detergent solution.

Biochimica et biophysica acta·2019
Same journal

Regulation of pigment content and enzyme activity in the cyanobacterium Nostoc sp. Mac grown in continuous light, a light-dark photoperiod, or darkness.

Biochimica et biophysica acta·2019
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.5K

Neuroproteomics tools in clinical practice.

Ganna Shevchenko1, Anne Konzer1, Sravani Musunuri1

  • 1Analytical Chemistry, Department of Chemistry-BMC and SciLife Lab, Uppsala University, 75124 Uppsala, Sweden.

Biochimica Et Biophysica Acta
|February 15, 2015
PubMed
Summary
This summary is machine-generated.

Mass spectrometry-based neuroproteomics accelerates biomarker discovery for neurodegenerative diseases like Alzheimer's and Parkinson's. This review highlights advances and future directions for precise, repeatable diagnostic and prognostic biomarkers.

Keywords:
Mass spectrometryNeurodegenerative diseaseProteomicsQuantitative neuroproteomics

More Related Videos

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

5.2K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

101

Related Experiment Videos

Last Updated: Apr 17, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.5K
Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

5.2K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

101

Area of Science:

  • Neuroscience
  • Neurology
  • Biomarker Discovery

Background:

  • Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS) involve neuronal impairment and protein changes.
  • Early diagnosis is challenging, necessitating precise and repeatable biomarkers.
  • Neuroproteomics offers potential for identifying disease-specific protein alterations.

Purpose of the Study:

  • To review recent advances in mass spectrometry-based neuroproteomics for neurodegenerative diseases.
  • To analyze current and future directions in biomarker discovery for these conditions.
  • To emphasize the need for clinically applicable diagnostic and prognostic biomarkers.

Main Methods:

  • Review of recent literature on mass spectrometry (MS) applications in neuroproteomics.
  • Analysis of studies focusing on biomarker identification in Alzheimer's disease, Parkinson's disease, and ALS.
  • Discussion of the role of proteomics in understanding disease-specific protein changes.

Main Results:

  • Mass spectrometry-based neuroproteomics is a rapidly advancing technology for biomarker discovery.
  • Significant progress has been made in identifying potential diagnostic and prognostic biomarkers.
  • The technology enables the detection of disease-specific protein signatures.

Conclusions:

  • Mass spectrometry-based neuroproteomics is crucial for accelerating biomarker discovery in neurodegenerative diseases.
  • Future research should focus on developing clinically validated biomarkers with high precision and repeatability.
  • This approach holds promise for improving early diagnosis and patient management.